Condition: HCC · Sponsor: Zhejiang Raygene Pharmaceuticals Co., Ltd
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.
This description comes directly from the study's public registry record.
Bill Shen, Ph.D. · 057185131875 · bill.shen@raygene.cn
Always discuss trial participation with your own doctor first.
| Zhongda Hospital, Affiliated to Southeast University | Nanjing, Jiangsu, China | Recruiting |
| Lishui Central Hospital | Lishui, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06844357